{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"40"}],"units":"Participants"}],"groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \\[MTD\\] identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG007","title":"Dose Expansion: AMG 224 Dose H + Prior CD38 Targeting Antibody Treatment"},{"description":"Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD identified based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"BG008","title":"Dose Expansion: AMG 224 Dose H + no Prior CD38 Targeting Antibody Treatment"},{"description":"Total of all reporting groups","id":"BG009","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.0","value":"63.3"},{"groupId":"BG001","spread":"3.8","value":"63.7"},{"groupId":"BG002","spread":"11.2","value":"64.3"},{"groupId":"BG003","spread":"4.0","value":"70.7"},{"groupId":"BG004","spread":"7.1","value":"60.5"},{"groupId":"BG005","spread":"5.7","value":"65.0"},{"groupId":"BG006","spread":"6.0","value":"58.2"},{"groupId":"BG007","spread":"8.7","value":"71.3"},{"groupId":"BG008","spread":"9.9","value":"53.0"},{"groupId":"BG009","spread":"8.4","value":"64.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"21"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"19"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"32"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"6"}],"title":"Black (or African American)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"25"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"8"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Safety analysis set: all participants that are enrolled and received at least 1 dose of AMG 224."}